查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1258889

到 2028 年的干细胞疗法市场预测——按产品类型、疗法、技术、应用、最终用户和地区进行的全球分析

Stem Cell Therapy Market Forecasts to 2028 - Global Analysis By Product, Therapy Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2022 年全球干细胞治疗市场将达到 2.57 亿美元，预计到 2028 年将达到 7.224 亿美元，预计将以 18.8 的复合年增长率增长%。

人类和动物都有干细胞，这是体内最有价值的细胞。 干细胞是能够增殖并长成体内所有类型细胞的细胞，可用于外科手术和医学。 有两种类型的干细胞：成体干细胞和胚胎干细胞。 胚胎干细胞是源自人类胚胎的干细胞 (ESC)。 这种细胞是多能的，可以发育成体内几乎任何类型的细胞。 干细胞疗法也被称为再生医学和中枢疗法。 再生医学具有再生细胞和替换受损或死亡细胞的能力。

根据国际癌症研究机构 2020 年的估计，五分之一的人会在生命中的某个阶段患上癌症，八分之一的男性和十一分之一的女性会死亡。它是

市场动态：

驱动程序：

慢性病患病率和发病率上升

慢性病影响着全世界大多数人。 世界上有三分之一的成年人患有慢性病。 许多人的健康和生活质量受到慢性病的负面影响。 癌症、肌肉骨骼和神经系统问题、慢性损伤、心血管和胃肠道疾病以及癌症都会导致住院、长期残疾、生活质量差和死亡。还有 间充质干细胞渗透并整合到各种器官中，用于治疗肺、脊髓、自身免疫、肝臟、骨骼和软骨疾病，以及多器官疾病。 使用干细胞治疗炎症性疾病、免疫系统疾病和退行性组织疾病是一种成功的途径。

抑制：

关于胚胎干细胞的伦理问题

对胚胎干细胞 (ESC) 治疗潜力的调查与许多与人类胚胎破坏相关的伦理问题有关。 未来，由于缺乏明确的联邦政策来定义胚胎干细胞研究和治疗开发将支持什么，可能会在一定程度上限制市场扩张。 此外，该领域法律的复杂性要求政府制定指导方针，以帮助研究人员、科学家和製药公司开发胚胎干细胞疗法并促进其商业化。

机会

干细胞研究的资助潜力

近年来，由于心血管、神经和自身免疫性疾病患者需要新的治疗方法，用于干细胞研究的资金有所增加。 2018年NIH对干细胞研究的资助创下新高，同比增长超过5%。 随着计划在 2021 年增加的贷款活动，这一趋势预计将继续下去。 例如，2021 年 9 月，加州再生医学研究所授予斯坦福研究院 3100 万美元，用于启动干细胞治疗心力衰竭、中风和脊髓肿瘤的首次人体研究。

威胁

昂贵的医疗费用

细胞疗法的高成本限制了市场扩张。 随着人们寻求最新的治疗方法，细胞疗法已发展成为一种突出的治疗方法。 儘管需求大幅增加，但细胞疗法仍然太昂贵而无法尝试。 视情况而定，一次简单的关节注射费用可能高达 1,000 美元，而更高级的手术费用可能高达 100,000 美元。 到 2020 年，美国干细胞疗法的平均费用预计将在每位患者 4,000 至 8,000 美元之间。 因此，高昂的治疗费用限制了干细胞治疗市场的扩张。

COVID-19 的影响：

COVID-19 大流行对干细胞治疗行业影响不大。 由于许多研究机构和政府机构专注于寻找快速有效的解决方案来治疗和预防像 COVID-19.rice field 这样的危险疾病，市场上出现了很多活动。 事实上，大流行已成为在全球范围内启动再生医学临床试验所需的动力。 几项临床试验已经证实，MSC 疗法可能是 COVID-19 患者的一种可行的治疗选择，尤其是那些患有急性呼吸窘迫综合征的患者。

预计在预测期内自体片段将是最大的

由于自体干细胞利用率的提高和各种干细胞产品的可用性，自体干细胞领域有望实现利润丰厚的增长。 细胞技术的最新进展导致对许多患病细胞及其新陈代谢的分子理解，增加了对治疗性干细胞疗法的需求。 可负担性、提高患者存活率、无需确定 HLA 匹配的供体以及移植物抗宿主病风险降低有望推动该领域的扩展。

预计在预测期内，电池采集部分的复合年增长率最高。

在预测期内，电池采集行业预计将实现最快的复合年增长率。 胚胎干细胞的发现为开发针对各种疾病的创新疗法铺平了道路。 这些细胞具有多能性，可用于在体内分化成许多不同的细胞类型。 然而，直接从胚胎中收集细胞在伦理上存在问题。 因此研究人员找到了另一种选择：iPS 细胞。 细胞采集进一步细分为骨髓采集、脐带血采集和单采。

市场份额最高的地区

由于强大的生物技术产业、主要参与者的主导地位、研发的巨大努力以及个性化医疗的推广，预计北美在预测期内将占据最大的市场份额。 此外，该领域的兴起可归因于政府为促进干细胞疗法而采取的更多举措。 例如，2020 年 3 月，加拿大政府投资约 700 万美元用于再生医学和干细胞研究。 这将通过资助九项跨境计划和四项临床试验来支持该国在再生医学领域的扩张。

复合年增长率最高的地区：

由于基于干细胞的药物的开发、政府对製造再生药物的努力、多个干细胞库的建立以及基因工程和生物医学研究的临床研究增加，亚太地区正在经历显着增长。,预计在预测期内表现出最高的复合年增长率。 例如，印度政府计划到 2022 年 2 月在 40 家顶级医学研究和教育机构拥有最先进的干细胞研究设施。

市场主要参与者

干细胞治疗市场的主要参与者包括：CORESTEM、Regrow Biosciences Pvt Ltd.、Takeda Pharmaceutical Company Limited、Medipost Co., Ltd.、Orthofix Holdings, Inc.、Smith & Nephew plc、Novadip Biosciences、Fuji Film Holding Co., Ltd.、Astellas Pharma Inc.、Allele Biotechnology and Pharmaceuticals, Inc.、NuVasive, Inc.、Mesoblast Co., Ltd.、Anterogen 和 AlloSource。

主要发展：

2022 年 7 月，CORESTEM（韩国）继续招募参与者参加 NeuroNata-R 的 3 期临床试验。 该疗法已在韩国获得有条件批准用于治疗 ALS 患者。

这份报告提供了什么

  • 区域级、国家级细分市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议等）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局和趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：基于可行性检查。）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球干细胞治疗市场：按产品分类

  • 人类胚胎干细胞 (HESC)
  • 非常小的类胚胎干细胞
  • 成体干细胞 (ASC)
    • 上皮/皮肤
    • 造血
    • 神经
    • 间充质系统
    • 其他成体干细胞 (ASC)
  • 诱导多能干细胞 (iPSC)

第 6 章全球干细胞疗法市场：按治疗类型分类

  • 同种异体
  • 首页

第 7 章全球干细胞治疗市场：按技术分类

  • 扩张和亚文化
  • 细胞生产
    • 细胞培养
    • 体外受精
    • 隔离
    • 治疗性克隆
  • 冷冻保存
  • 获取单元格
    • 单采术
    • 骨髓采集
    • 脐带血

第 8 章全球干细胞治疗市场：按应用

  • 药物发现和开发

再生医学

    • 糖尿病
    • 尿失禁
    • 肿瘤学
    • 心血管和心肌梗塞
    • 神经学
    • 受伤
    • 骨科
    • 肝损伤
    • 血液学
    • 其他再生医学

第 9 章全球干细胞治疗市场：按最终用户分类

  • 学术和研究机构
  • 製药和生物技术公司
  • 医院和细胞库

第 10 章全球干细胞治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第11章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • CORESTEM
  • Regrow Biosciences Pvt Ltd.
  • Takeda Pharmaceutical Company Limited
  • MEDIPOST Co., Ltd.
  • Orthofix Holdings, Inc.
  • Smith & Nephew plc
  • Novadip Biosciences
  • Fujifilm Holding Corporation
  • Astellas Pharma Inc.
  • Allele Biotechnology and Pharmaceuticals, Inc.
  • NuVasive, Inc.
  • Mesoblast Ltd.
  • Anterogen.Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • AlloSource
Product Code: SMRC22769

According to Stratistics MRC, the Global Stem Cell Therapy Market is accounted for $257 million in 2022 and is expected to reach $722.4 million by 2028 growing at a CAGR of 18.8% during the forecast period. Humans and animals both have stem cells, which are the most valuable cells in the body. Stem cells are cells that have the ability to proliferate and grow into practically any cell type in the body, and they are used in surgery and medicine. There are two types of stem cells: adult stem cells and embryonic stem cells. Embryonic stem cells are stem cells derived from human embryos (ESCs). They are pluripotent, which means they can develop into almost any type of cell in the body. Stem cell therapy is also known as regenerative medicine or centrepiece therapy. Regenerative medications have the ability to regenerate cells and replace those that have been damaged or perished.

According to estimates from the International Agency for Research on Cancer 2020, 1 in 5 people will develop cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will pass away.

Market Dynamics:

Driver:

The rise in prevalence and incidence of chronic diseases

Chronic illnesses affect the vast majority of individuals worldwide. One in in three adults globally suffers from a chronic illness. Many people's health and quality of life have been negatively influenced by chronic diseases. Cancer, musculoskeletal and neurological problems, chronic injuries, cardiovascular and gastrointestinal conditions, and cancer can all lead to hospitalisation, long-term incapacity, a reduction in quality of life, and even death. Mesenchymal stem cells penetrate and integrate into various organs, treating lung, spinal cord, autoimmune illnesses, liver, bone, and cartilage diseases, and treating multiple organ damage. The use of stem cells in the treatment of inflammatory, immune system, and degenerative tissue diseases is a successful method.

Restraint:

Ethical concerns related to embryonic stem cells

Research into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of ethical concerns related to the destruction of human embryos. In the future, a lack of clear federal policies defining what can be supported in embryo-based stem cell research or therapy development may limit market expansion to some extent. Furthermore, the complexities of legislation in this sector necessitate government guidelines that can assist researchers, scientists, and pharmaceutical companies in developing ESC therapy and facilitating its commercialization.

Opportunity:

Availability of funding for stem cell research

Stem cell research funding has increased in recent years, owing to the need for novel therapeutic approaches in patients with cardiovascular, neurological, and autoimmune illnesses. The NIH funding for stem cell research reached a new high in 2018, with a year-on-year increase of more than 5%. This trend is projected to continue with the increase in financing efforts planned in 2021. For example, in September 2021, the California Institute for Regenerative Medicine awarded Stanford Research a USD 31 million funding to launch first-in-human studies of stem cells in the treatment of heart failure, stroke, and spinal cord tumours.

Threat:

High cost of treatment

The high cost of cell therapy has limited market expansion. Cell therapies have developed as a prominent treatment option as people seek out the most recent therapy options. Despite the significant increase in demand, cell therapies remain too expensive to try. Simple joint injections can cost up to $1,000 depending on the situation, whereas more sophisticated surgeries might cost up to $100,000. The average cost of stem cell therapy in the United States is expected to be between $4,000 and $8,000 per patient in 2020. As a result, the high cost of treatment limits the expansion of the stem cell therapy market.

COVID-19 Impact:

The COVID-19 pandemic had little effect on the stem cell therapy industry. The market saw a lot of activity because many research and government entities were focused on finding rapid and effective solutions to cure and prevent dangerous disorders like COVID-19. In fact, the pandemic provided the impetus needed to launch worldwide regenerative medicine clinical trials. Several clinical investigations have confirmed that MSC therapy could be a viable treatment option for COVID-19 patients, particularly those with acute respiratory distress syndrome.

The autologous segment is expected to be the largest during the forecast period

The autologous segment is estimated to have a lucrative growth, because of the increased usage of autologous stem cells and the availability of a variety of stem cell products. Recent advances in cellular technology have contributed to a better understanding of numerous disease cells and their metabolism at the molecular level, pushing the demand for stem cell therapies for treatment. Affordability, better patient survival rate, no need to identify an HLA-matched donor, and minimal risk of graft-versus-host disease are all expected to drive the expansion of this segment.

The cell acquisition segment is expected to have the highest CAGR during the forecast period

The cell acquisition segment is anticipated to witness the fastest CAGR growth during the forecast period. The discovery of embryonic stem cells has paved the path for the development of innovative treatments for a variety of ailments. These cells are pluripotent, which means they can be utilised to differentiate many different types of cells in the body. Obtaining embryonic cells directly from the embryo, on the other hand, has created ethical difficulties. As a result, researchers discovered an alternative-iPS cells. Cell acquisition is further subdivided into bone marrow harvest, umbilical blood cord harvest, and apheresis.

Region with highest share:

North America is projected to hold the largest market share during the forecast period, because of the robust biotechnology industry, the domination of major key firms, considerable R&D efforts, and the promotion of individualised medications. Furthermore, this sector's rise can be attributable to a growing government initiative to promote stem cell therapy. For example, in March 2020, the Canadian government invested around USD 7 million towards regenerative medicine and stem cell research. It will support the country's expansion in the regenerative medicine sector by funding nine transnational initiatives and four clinical trials.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, because of the development of stem cell-based medicines, government initiatives for producing regenerative drugs, the establishment of multiple stem cell banks, and the region's growing clinical studies for genetic engineering and biomedical research. For example, the government of India has established cutting-edge stem cell research facilities in 40 top health research and educational institutes by February 2022.

Key players in the market:

Some of the key players profiled in the Stem Cell Therapy Market include: CORESTEM, Regrow Biosciences Pvt Ltd., Takeda Pharmaceutical Company Limited, MEDIPOST Co., Ltd., Orthofix Holdings, Inc., Smith & Nephew plc, Novadip Biosciences, Fujifilm Holding Corporation, Astellas Pharma Inc., Allele Biotechnology and Pharmaceuticals, Inc., NuVasive, Inc., Mesoblast Ltd., Anterogen.Co., Ltd.,JCR Pharmaceuticals Co., Ltd. and AlloSource.

Key Developments:

In July 2022, CORESTEM (South Korea) continued enrolling participants for the Phase 3 clinical trial of NeuroNata-R. This therapy has received conditional approval for treating ALS patients in South Korea.

Products Covered:

  • Human Embryonic Stem Cells (HESCs)
  • Very Small Embryonic Like Stem Cells
  • Adult Stem Cells (ASCs)
  • Induced Pluripotent Stem Cells (iPSCs)

Therapy Types Covered:

  • Allogenic
  • Autologous

Technologies Covered:

  • Expansion and Sub-Culture
  • Cell Production
  • Cryopreservation
  • Cell Acquisition

Applications Covered:

  • Drug Discovery and Development
  • Regenerative Medicine

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Cell Banks

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Stem Cell Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Human Embryonic Stem Cells (HESCs)
  • 5.3 Very Small Embryonic Like Stem Cells
  • 5.4 Adult Stem Cells (ASCs)
    • 5.4.1 Epithelial/Skin
    • 5.4.2 Hematopoietic
    • 5.4.3 Neural
    • 5.4.4 Mesenchymal
    • 5.4.5 Other Adult Stem Cells (ASCs)
  • 5.5 Induced Pluripotent Stem Cells (iPSCs)

6 Global Stem Cell Therapy Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Allogenic
  • 6.3 Autologous

7 Global Stem Cell Therapy Market, By Technology

  • 7.1 Introduction
  • 7.2 Expansion and Sub-Culture
  • 7.3 Cell Production
    • 7.3.1 Cell Culture
    • 7.3.2 In-vitro Fertilization
    • 7.3.3 Isolation
    • 7.3.4 Therapeutic Cloning
  • 7.4 Cryopreservation
  • 7.5 Cell Acquisition
    • 7.5.1 Apheresis
    • 7.5.2 Bone Marrow Harvest
    • 7.5.3 Umbilical Blood Cord

8 Global Stem Cell Therapy Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery and Development

Regenerative Medicine

    • 8.3.1 Diabetes
    • 8.3.2 Incontinence
    • 8.3.3 Oncology
    • 8.3.4 Cardiovascular and Myocardial Infraction
    • 8.3.5 Neurology
    • 8.3.6 Injuries
    • 8.3.7 Orthopedics
    • 8.3.8 Liver Disorder
    • 8.3.9 Hematology
    • 8.3.10 Other Regenerative Medicines

9 Global Stem Cell Therapy Market, By End User

  • 9.1 Introduction
  • 9.2 Academic & Research Institutes
  • 9.3 Pharmaceutical & Biotechnology Companies
  • 9.4 Hospitals & Cell Banks

10 Global Stem Cell Therapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 CORESTEM
  • 12.2 Regrow Biosciences Pvt Ltd.
  • 12.3 Takeda Pharmaceutical Company Limited
  • 12.4 MEDIPOST Co., Ltd.
  • 12.5 Orthofix Holdings, Inc.
  • 12.6 Smith & Nephew plc
  • 12.7 Novadip Biosciences
  • 12.8 Fujifilm Holding Corporation
  • 12.9 Astellas Pharma Inc.
  • 12.10 Allele Biotechnology and Pharmaceuticals, Inc.
  • 12.11 NuVasive, Inc.
  • 12.12 Mesoblast Ltd.
  • 12.13 Anterogen.Co., Ltd.
  • 12.14 JCR Pharmaceuticals Co., Ltd.
  • 12.15 AlloSource

List of Tables

  • Table 1 Global Stem Cell Therapy Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Stem Cell Therapy Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global Stem Cell Therapy Market Outlook, By Human Embryonic Stem Cells (HESCs) (2020-2028) ($MN)
  • Table 4 Global Stem Cell Therapy Market Outlook, By Very Small Embryonic Like Stem Cells (2020-2028) ($MN)
  • Table 5 Global Stem Cell Therapy Market Outlook, By Adult Stem Cells (ASCs) (2020-2028) ($MN)
  • Table 6 Global Stem Cell Therapy Market Outlook, By Epithelial/Skin (2020-2028) ($MN)
  • Table 7 Global Stem Cell Therapy Market Outlook, By Hematopoietic (2020-2028) ($MN)
  • Table 8 Global Stem Cell Therapy Market Outlook, By Neural (2020-2028) ($MN)
  • Table 9 Global Stem Cell Therapy Market Outlook, By Mesenchymal (2020-2028) ($MN)
  • Table 10 Global Stem Cell Therapy Market Outlook, By Other Adult Stem Cells (ASCs) (2020-2028) ($MN)
  • Table 11 Global Stem Cell Therapy Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2020-2028) ($MN)
  • Table 12 Global Stem Cell Therapy Market Outlook, By Therapy Type (2020-2028) ($MN)
  • Table 13 Global Stem Cell Therapy Market Outlook, By Allogenic (2020-2028) ($MN)
  • Table 14 Global Stem Cell Therapy Market Outlook, By Autologous (2020-2028) ($MN)
  • Table 15 Global Stem Cell Therapy Market Outlook, By Technology (2020-2028) ($MN)
  • Table 16 Global Stem Cell Therapy Market Outlook, By Expansion and Sub-Culture (2020-2028) ($MN)
  • Table 17 Global Stem Cell Therapy Market Outlook, By Cell Production (2020-2028) ($MN)
  • Table 18 Global Stem Cell Therapy Market Outlook, By Cell Culture (2020-2028) ($MN)
  • Table 19 Global Stem Cell Therapy Market Outlook, By In-vitro Fertilization (2020-2028) ($MN)
  • Table 20 Global Stem Cell Therapy Market Outlook, By Isolation (2020-2028) ($MN)
  • Table 21 Global Stem Cell Therapy Market Outlook, By Therapeutic Cloning (2020-2028) ($MN)
  • Table 22 Global Stem Cell Therapy Market Outlook, By Cryopreservation (2020-2028) ($MN)
  • Table 23 Global Stem Cell Therapy Market Outlook, By Cell Acquisition (2020-2028) ($MN)
  • Table 24 Global Stem Cell Therapy Market Outlook, By Apheresis (2020-2028) ($MN)
  • Table 25 Global Stem Cell Therapy Market Outlook, By Bone Marrow Harvest (2020-2028) ($MN)
  • Table 26 Global Stem Cell Therapy Market Outlook, By Umbilical Blood Cord (2020-2028) ($MN)
  • Table 27 Global Stem Cell Therapy Market Outlook, By Application (2020-2028) ($MN)
  • Table 28 Global Stem Cell Therapy Market Outlook, By Drug Discovery and Development (2020-2028) ($MN)
  • Table 29 Global Stem Cell Therapy Market Outlook, By Regenerative Medicine (2020-2028) ($MN)
  • Table 30 Global Stem Cell Therapy Market Outlook, By Diabetes (2020-2028) ($MN)
  • Table 31 Global Stem Cell Therapy Market Outlook, By Incontinence (2020-2028) ($MN)
  • Table 32 Global Stem Cell Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 33 Global Stem Cell Therapy Market Outlook, By Cardiovascular and Myocardial Infraction (2020-2028) ($MN)
  • Table 34 Global Stem Cell Therapy Market Outlook, By Neurology (2020-2028) ($MN)
  • Table 35 Global Stem Cell Therapy Market Outlook, By Injuries (2020-2028) ($MN)
  • Table 36 Global Stem Cell Therapy Market Outlook, By Orthopedics (2020-2028) ($MN)
  • Table 37 Global Stem Cell Therapy Market Outlook, By Liver Disorder (2020-2028) ($MN)
  • Table 38 Global Stem Cell Therapy Market Outlook, By Hematology (2020-2028) ($MN)
  • Table 39 Global Stem Cell Therapy Market Outlook, By Other Regenerative Medicines (2020-2028) ($MN)
  • Table 40 Global Stem Cell Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 41 Global Stem Cell Therapy Market Outlook, By Academic & Research Institutes (2020-2028) ($MN)
  • Table 42 Global Stem Cell Therapy Market Outlook, By Pharmaceutical & Biotechnology Companies (2020-2028) ($MN)
  • Table 43 Global Stem Cell Therapy Market Outlook, By Hospitals & Cell Banks (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.